Venture capital (VC) is an "endangered species," with rapidly diminishing investments in early-stage, high-risk biotechs. Of note, Series A/seed funding investments declined steadily from a peak of 10 transactions in 2007 to...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)